Corcept Therapeutics (CORT)
Develops cortisol-modulating medicines for endocrine disease and cancer.
$117.20
After hours−0.26 (−0.22%)
At close$117.46(+3.25%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 124 | 135 | 147 | 164 | 183 | 182 | 157 | 194 | 208 | 202 | 165 | 256 |
| Cost of revenue | 2 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 5 | 3 | 3 | 4 |
| Gross profit | 122 | 134 | 144 | 161 | 180 | 179 | 155 | 191 | 203 | 200 | 162 | 252 |
| 91 | 102 | 115 | 126 | 133 | 154 | 151 | 164 | 193 | 195 | 212 | 211 | |
| Research & development | 46 | 55 | 59 | 59 | 59 | 70 | 61 | 60 | 69 | 65 | 66 | 54 |
| Selling, general & administrative | 45 | 47 | 56 | 67 | 74 | 83 | 91 | 104 | 124 | 130 | 145 | 157 |
| Other expenses | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | 31 | 32 | 30 | 36 | 47 | 25 | 3 | 27 | 10 | 4 | −50 | 41 |
| 5 | 5 | 5 | 6 | 6 | 7 | 6 | 5 | 5 | 5 | 5 | 5 | |
| Interest income | 5 | 5 | 5 | 6 | 6 | 7 | 6 | 5 | 5 | 5 | 5 | 0 |
| Other non-operating income | 0 | −5 | −5 | −6 | −6 | −7 | −6 | −5 | −5 | −5 | −5 | −5 |
| Income before tax | 36 | 37 | 35 | 42 | 53 | 32 | 10 | 32 | 15 | 10 | −45 | 46 |
| Income tax expense | 5 | 5 | 7 | 6 | 6 | 1 | −11 | −3 | −4 | −14 | −14 | −3 |
| Net income from continuing operations | 31 | 31 | 28 | 35 | 47 | 31 | 21 | 35 | 20 | 24 | −31 | 49 |
| Other adjustments | 0 | 0 | 0 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | 31 | 31 | 28 | 35 | 47 | 30 | 21 | 35 | 20 | 24 | −31 | 42 |
| EPS, basic | $0.31 | $0.30 | $0.27 | $0.34 | $0.45 | $0.29 | $0.19 | $0.33 | $0.19 | $0.23 | −$0.30 | $0.40 |
| EPS, diluted | $0.28 | $0.28 | $0.25 | $0.32 | $0.41 | $0.26 | $0.17 | $0.29 | $0.16 | $0.20 | −$0.30 | $0.36 |
| Weighted average shares, basic | 102 | 102 | 103 | 103 | 103 | 104 | 104 | 104 | 104 | 104 | 104 | 105 |
| Weighted average shares, diluted | 111 | 111 | 110 | 111 | 114 | 118 | 120 | 120 | 119 | 120 | 104 | 118 |
| EBITDA | 31 | 37 | 35 | 42 | 53 | 32 | 10 | 32 | 16 | 10 | −44 | 47 |
| Depreciation & amortization | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| EBIT | 31 | 37 | 35 | 42 | 53 | 32 | 10 | 32 | 15 | 10 | −45 | 46 |